spermatogenesis associated 2 likeGenealiases: C16orf76 · tamo
Q-omics provides the consensus-scored SPATA2L profile across patient tissues and cancer cell-line models. SPATA2L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SPATA2L is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, SPATA2L RNA expression shows 17,951 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KICH, and THYM as cancer lineages where SPATA2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPATA2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPATA2L survival associations across molecular data types. SPATA2L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPATA2L RNA expression–survival associations across cancer types. High SPATA2L expression shows unfavorable associations in UCS, ACC, LGG, BLCA and LIHC, but favorable associations in SCLC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for SPATA2L RNA expression.
This table summarizes SPATA2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SPATA2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPATA2L shows lower tumor expression in KICH and LUSC and higher tumor expression in COAD, HNSC, STAD and LIHC. The KICH box plot shows higher SPATA2L RNA expression in normal versus tumor tissue (log2 FC = −1.681, t-test p < 0.001).
This table shows molecular features associated with SPATA2L in patient tissues and cancer cell lines. In patient samples, SPATA2L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPATA2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
